Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants

Journal of Virology

Volumn 75, Issue 15, 2001, Pages 7202-7205

  Lennerstrand, J ^a   Hertogs, K ^a   Stammers, D K ^a   Larder, B A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; CONCENTRATION RESPONSE; CORRELATION FUNCTION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PYROLYSIS; SITE DIRECTED MUTAGENESIS; VIRUS MUTANT; VIRUS MUTATION; VIRUS RESISTANCE;

ADENOSINE TRIPHOSPHATE; ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; GUANOSINE TRIPHOSPHATE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; MUTAGENESIS, SITE-DIRECTED; REVERSE TRANSCRIPTASE INHIBITORS; THYMINE NUCLEOTIDES; ZIDOVUDINE;

EID: 0034948070     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.15.7202-7205.2001     Document Type: Article

References (26)

1. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): Increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase
2. Luminescent immobilized enzyme test systems for inorganic pyrophosphate: Assays using firefly luciferase and nicotinamidemononucleotide adenylyl transferase or adenosine-5′-triphosphate sulfurylase
3. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
4. A sensitive assay for the quantification of reverse transcriptase activity based on the use of carrier-bound template and non-radioactive-product detection, with special reference to human-immunodeficiency-virus isolation
5. Infection of HTLV-III/ LAV in HTLV-I.carrying cells MT-2 and MT-4 and application in a plaque assay
6. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility
7. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
8. Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates
9. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine
10. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC
11. Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3′-azido-3′-deoxythymidine
12. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing
13. IV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
14. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type I reverse transcriptase confer multinucleoside analog resistance
15. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)
16. Related functional domains in virus DNA polymerases
17. Application of a chain termination assay for characterisation of reverse transcriptase from AZT-resistant HIV isolates
18. Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance
19. A mechanism of AZT resistance: An increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase
20. A non-radioactive microtitre plate reverse transcriptase (RT) assay, based on immobilized template, for screening of RT activity inhibitors and evaluation of their mode of action
21. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides
22. Crystals of HIV-1 reverse transcriptase diffracting to 2.2 Å resolution
23. Physiological concentrations of purines and pyrimidines
24. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2′,3′-dideoxynucleoside 5′-triphosphates
25. Anti-human immunodeficiency virus drug combination strategies
26. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors